77123-59-2

Usage

Uses

Used in Organic Synthesis:
Methyl 3-((triMethylsilyl)ethynyl)benzoate is used as a key intermediate in organic synthesis for the preparation of various organic molecules and materials. Its unique structure allows for a wide range of reactions, making it a valuable building block in the synthesis of complex organic compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, Methyl 3-((triMethylsilyl)ethynyl)benzoate is used as a reagent in the production of various pharmaceuticals. Its functional groups and reactivity make it suitable for the synthesis of drug molecules, contributing to the development of new medications.
Used in Agrochemical Production:
Methyl 3-((triMethylsilyl)ethynyl)benzoate also finds application in the agrochemical industry, where it is used in the synthesis of various agrochemicals. Its versatility in chemical reactions allows for the creation of compounds that can be used in agriculture to improve crop yields and protect plants from pests.
Used in Materials Science:
In the field of materials science, Methyl 3-((triMethylsilyl)ethynyl)benzoate is utilized for the development of new materials with unique properties. Its ability to participate in a variety of chemical reactions enables the creation of materials with specific characteristics, such as improved strength, flexibility, or chemical resistance.

Upstream product

• 618-89-3 methyl 3-bromobenzoate 
• 1066-54-2 trimethylsilylacetylene 
• 618-91-7 methyl 3-iodo-benzoate 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 618-51-9 3-Iodobenzoic acid 

Downstream Products

• 110598-52-2 3-[1-(4-Hydroxy-phenyl)-vinyl]-benzoic acid methyl ester 
• 110598-34-0 3-[(Z)-1-(4-Hydroxy-phenyl)-2-trimethylsilanyl-vinyl]-benzoic acid methyl ester 
• 110598-44-2 3-[(Z)-2-(4-Hydroxy-phenyl)-2-trimethylsilanyl-vinyl]-benzoic acid methyl ester 
• 10602-06-9 methyl 3-ethynylbenzoate 
• 21860-07-1 methyl 3-acetylbenzoate 
• 1316650-01-7 C₂₂H₁₈N₄O₃ 
• 1316649-98-5 C₁₇H₁₆N₄O₃ 
• 1316649-97-4 C₂₀H₂₂N₄O₂ 
• 1316649-95-2 C₁₉H₂₀N₄O₂ 
• 1316649-91-8 C₁₈H₁₈N₄O₂ 
• 1316652-41-1 (N-hydroxy-3-(1-phenylsulfanylmethyl-1H-[1,2,3]triazol-4-yl)benzamide) 
• 1316652-25-1 (N-hydroxy-3-[1-(2-thiophen-3-ylethyl)-1H-[1,2,3]triazol-4-yl]benzamide) 
• 1316649-90-7 C₁₇H₁₆N₄O₂ 
• 1316649-89-4 C₁₆H₁₄N₄O₂ 

Relevant academic research and scientific papers

Chemoselective Cleavage of Si-C(sp3) Bonds in Unactivated Tetraalkylsilanes Using Iodine Tris(trifluoroacetate)

Organosilanes are synthetically useful reagents and precursors in organic chemistry. However, the typical inertness of unactivated Si-C(sp3) bonds under conventional reaction conditions has hampered the application of simple tetraalkylsilanes in organic synthesis. Herein we report the chemoselective cleavage of Si-C(sp3) bonds of unactivated tetraalkylsilanes using iodine tris(trifluoroacetate). The reaction proceeds smoothly under mild conditions (-50 °C to room temperature) and tolerates various polar functional groups, thus enabling subsequent Tamao-Fleming oxidation to provide the corresponding alcohols. NMR experiments and density functional theory calculations on the reaction indicate that the transfer of alkyl groups from Si to the I(III) center and the formation of the Si-O bond proceed concertedly to afford an alkyl-λ3-iodane and silyl trifluoroacetate. The developed method enables the use of unactivated tetraalkylsilanes as highly stable synthetic precursors.

Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity

Breakpoint cluster region-Abelson (Bcr-Abl) kinase is a key driver in the pathophysiology of chronic myelogenous leukemia (CML). Broadening the chemical diversity of Bcr-Abl kinase inhibitors with novel chemical entities possessing favorable target potency and cellular efficacy is a current medical demand for CML treatment. In this respect, a new series of ethynyl bearing 3-aminoindazole based Bcr-Abl inhibitors has been designed, synthesized, and biologically evaluated. The target compounds were designed based on introducing the key structural features of ponatinib, alkyne spacer and diarylamide, into the previously reported indazole II to improve its Bcr-Abl inhibitory activity and overcome its poor cellular potency. All target compounds elicited potent activity against Bcr-AblWT with sub-micromolar IC50 values ranging 4.6–667 nM. In addition, certain derivatives exhibited promising potency over the clinically imatinib-resistant Bcr-AblT315I. Among the target molecules, compounds 9c, 9h and 10c stood as the most potent derivatives with IC50 values of 15.4 nM, 4.6 nM, and 25.8 nM, respectively, against Bcr-AblWT. Interestingly, 9h showed 2 folds and 3.6 times superior potency to the lead indazole II and 10c, respectively, against Bcr-AblT315I. Molecular docking of 9h pointed out its possibility to be a type II kinase inhibitor. Furthermore, all compounds, except 9b, showed highly potent antiproliferative activity against the Bcr-Abl positive leukemia K562 cell (MTT assay) surpassing the modest activity of lead indazole II. Moreover, the most potent members 9h and 10c exerted potent antileukemic activity against NCI leukemia panel, particularly K562 cell (SRB assay) with GI50 less than 10 nM, being superior to the FDA approved drug imatinib. Further biochemical hERG and cellular toxicity, phosphorylation assay, and NanoBRET target engagement of 9h underscored its merits as a promising candidate for CML therapy.

NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME

Disclosed are a compound selected from novel indazole derivatives, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, and a pharmaceutical composition for preventing, alleviating or treating cancer containing the compound as an active ingredient. The novel indazole derivatives exhibit excellent ABL/DDR1 inhibitory efficacy and anti-proliferative efficacy against cancer cells, specifically blood cancer cells, and inhibitory activity against ABL T315I point mutations, thus being useful for the prevention, alleviation or treatment of cancer, specifically blood cancer, especially chronic myelogenous leukemia.

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

DISUBSTITUTED ALKYNE DERIVATIVES

The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

Pyrtriazoles, a Novel Class of Store-Operated Calcium Entry Modulators: Discovery, Biological Profiling, and in Vivo Proof-of-Concept Efficacy in Acute Pancreatitis

In recent years, channels that mediate store-operated calcium entry (SOCE, i.e., the ability of cells to sense a decrease in endoplasmic reticulum luminal calcium and induce calcium entry across the plasma membrane) have been associated with a number of d

A fragment-based approach for the development of g-quadruplex ligands: Role of the amidoxime moiety

G-quadruplex (G4) nucleic acid structures have been reported to be involved in several human pathologies, including cancer, neurodegenerative disorders and infectious diseases; however, G4 targeting compounds still need implementation in terms of drug-lik

Using the same hydroxamic acid derivative and HDAC8 inhibitor (by machine translation)

Disclosed are: a compound which is capable of inhibiting the function of HDAC8; and an HDAC8 inhibitor. Specifically disclosed is a hydroxamic acid derivative which is characterized by being composed of a compound represented by general formula (1) (wherein X represents an aromatic substituent or an optionally substituted 3-8 membered ring, and n represents an integer of 0-20), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS

The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis.

Palladium-catalyzed trifluoroethylation of terminal alkynes with 1,1,1-trifluoro-2-iodoethane

An efficient Csp-CH2CF3 bond-forming reaction via Pd-catalyzed 2,2,2-trifluoroethylation of aryl and alkyl terminal alkynes has been developed. This protocol proceeds under mild conditions using the readily available and cheap reagent CF3CH2I as the source of the CH2CF3 group. Various terminal aryl alkynes as well as alkylacetylenes can be transformed into the corresponding trifluoroethylated products in good-to-excellent yields. The method is tolerant of carbonyl, nitro, ester, cyano, and even formyl groups.